Impact of Anesthesia Maintenance Methods on Long-term Survival

Summary

Surgery is one of the major treatment methods for patients with malignant tumor. And, alone with the ageing process, more and more elderly patients undergo surgery for malignant tumor. Evidence emerges that choice of anesthetics, i.e., either inhalational or intravenous anesthetics, may influence the outcome of elderly patients undergoing cancer surgery. From the point of view of immune function after surgery and invasiveness of malignant tumor cells, propofol intravenous anesthesia may be superior to inhalational anesthesia. However, the clinical significance of these effects remains unclear. Retrospective studies indicated that use of propofol intravenous anesthesia was associated higher long-term survival rate. Prospective studies exploring the effect of anesthetic choice on long-term survival in cancer surgery patients are urgently needed.

Conditions

• Aged
• Neoplasms
• Surgical Procedure, Operative
• Anesthesia, Inhalation
• Anesthesia, Intravenous
• Survival

Interventions

DRUG

Sevoflurane

Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.

DRUG

Propofol

Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.

Sponsors & Collaborators

• Hebei Medical University Fourth Hospital

  collaborator OTHER

• The People's Hospital of Ningxia

  collaborator OTHER

• Beijing Shijitan Hospital, Capital Medical University

  collaborator OTHER

• Guizhou Provincial People's Hospital

  collaborator OTHER

• Affiliated Hospital of Qinghai University

  collaborator OTHER

• The Third Xiangya Hospital of Central South University

  collaborator OTHER

• Cancer Hospital of Guangxi Medical University

  collaborator OTHER

• Shanxi Provincial People's Hospital

  collaborator OTHER_GOV

• Zhongda Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• Tang-Du Hospital

  collaborator OTHER

• Tianjin Nankai Hospital

  collaborator OTHER

• Shenzhen Second People's Hospital

  collaborator OTHER

• Peking University First Hospital

  lead OTHER

Principal Investigators

• Dong-Xin Wang, MD, PhD · Peking University First Hospital

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

65 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-04-01

Primary Completion

2017-09-29

Completion

2020-09-30

Countries

• China

Study Locations